Semaglutide vs Tirzepatide: Which GLP-1 Medication Is Right for You?

The Two Giants of Modern Weight Loss Medicine

If you've been researching medical weight loss in 2025, two names dominate every conversation: semaglutide (branded as Ozempic and Wegovy) and tirzepatide (branded as Mounjaro and Zepbound). Both are GLP-1 receptor agonists. Both produce remarkable weight loss. But they are not identical — and understanding the differences matters when deciding which one is right for your body.

How They Work: The Science

Semaglutide mimics the GLP-1 hormone, suppressing appetite and slowing gastric emptying. Tirzepatide goes further — it's a dual agonist, targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism appears to provide stronger metabolic effects in many users.

Which Should You Choose?

The honest answer: it depends on your metabolic profile, your goals, and how your body responds. Some users tolerate semaglutide better; others see dramatically better results on tirzepatide. This is exactly why self-prescribing based on Instagram posts is a bad idea — and why MetaFit's doctor-led evaluation process exists.

2026 Cost Update: The Price Picture Has Changed

Cost is now a major deciding factor. Since semaglutide's Indian patent expired in March 2026, generic versions have dropped its price to roughly ₹1,300–₹4,200/month, while tirzepatide (still patent-protected until ~2036) ranges from about ₹13,125 to ₹25,781/month. Dig into the details in our dedicated guides: generic semaglutide in India and Mounjaro cost in India 2026. New to GLP-1? Start with our complete GLP-1 weight loss guide.